Why did the draft revision of the Drug Administration Law "fail", the answer is here

On April 23, the 10th meeting of the Standing Committee of the 13th National People's Congress conducted a second review of the "Drug Administration Law of the People's Republic of China (Revised Draft)" and the "People's Republic of China Vaccine Administration Law (Draft)"

According to the "Legislative Law of the People's Republic of China", the formulation of laws generally has several stages, such as proposing a bill, deliberating, amending, voting, and publishing

18 years later!

It took 17 years from the first legislation in 1984 to the first revision in 2001.

Xinhua News Agency commented on the move.

On the evening of April 23, a number of industry media published articles with titles such as "New Drug Administration Law "Issued to be Supplemented"? "Not Passed", "misunderstanding" the results of the second review

"Three-trial system" of the Standing Committee

According to Article 29 of the Legislative Procedures of the Standing Committee of the National People's Congress, Section 3 of the Legislative Law of the People's Republic of China, "A bill that is listed on the agenda of a meeting of the Standing Committee shall generally be considered at three meetings of the Standing Committee before being put to vote

Source: Drug Legislation Law of the People's Republic of China (2015 Amendment)

Simply put, after a draft law is submitted to the Standing Committee of the National People's Congress for deliberation, it generally goes through three meetings of the Standing Committee for deliberation

Section 3 of the Legislative Law of the People's Republic of China, Article 30 of the Legislative Procedures of the Standing Committee of the National People's Congress stipulates that a bill on the agenda of a meeting of the Standing Committee, if the opinions of all parties are relatively consistent, may be deliberated at two meetings of the Standing Committee The bills with relatively single adjustment or partial amendments, where the opinions of all parties are relatively consistent, may also be put to vote after deliberation at a meeting of the Standing Committee

Regarding the multiple interest demands of the "Drug Administration Law" involving entities or individuals engaged in the research, production, operation, use, and supervision and management of drugs in China, it is difficult to achieve a relatively unanimous opinion in a short period of time, and there may even be major differences.

Here we look forward to the early entry of the "Drug Administration Law" into the third trial of the Standing Committee!